Showing results (111-120 of 241) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Scientific Reports|February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignanciesYudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Oncotarget|September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinicVikas Dembla, Neeta Somaiah, Pedro Barata, et al.
Signal Transduction and Targeted Therapy|February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncologyStephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.
Investigational New Drugs|November 4, 2014
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.
British Journal of Cancer|March 6, 2021
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignanciesShuyang Yao, Filip Janku, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialAna M Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, et al.
Gynecologic Oncology Research and Practice|May 28, 2016
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experienceSiqing Fu, Naiyi Shi, Jennifer Wheler, et al.
Pageof 25